These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1724 related articles for article (PubMed ID: 34525275)

  • 1. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
    Bar-On YM; Goldberg Y; Mandel M; Bodenheimer O; Freedman L; Kalkstein N; Mizrahi B; Alroy-Preis S; Ash N; Milo R; Huppert A
    N Engl J Med; 2021 Oct; 385(15):1393-1400. PubMed ID: 34525275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against Covid-19 by BNT162b2 Booster across Age Groups.
    Bar-On YM; Goldberg Y; Mandel M; Bodenheimer O; Freedman L; Alroy-Preis S; Ash N; Huppert A; Milo R
    N Engl J Med; 2021 Dec; 385(26):2421-2430. PubMed ID: 34879188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BNT162b2 Vaccine Booster and Mortality Due to Covid-19.
    Arbel R; Hammerman A; Sergienko R; Friger M; Peretz A; Netzer D; Yaron S
    N Engl J Med; 2021 Dec; 385(26):2413-2420. PubMed ID: 34879190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waning Immunity after the BNT162b2 Vaccine in Israel.
    Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman L; Haas EJ; Milo R; Alroy-Preis S; Ash N; Huppert A
    N Engl J Med; 2021 Dec; 385(24):e85. PubMed ID: 34706170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
    Bar-On YM; Goldberg Y; Mandel M; Bodenheimer O; Amir O; Freedman L; Alroy-Preis S; Ash N; Huppert A; Milo R
    N Engl J Med; 2022 May; 386(18):1712-1720. PubMed ID: 35381126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
    Magen O; Waxman JG; Makov-Assif M; Vered R; Dicker D; Hernán MA; Lipsitch M; Reis BY; Balicer RD; Dagan N
    N Engl J Med; 2022 Apr; 386(17):1603-1614. PubMed ID: 35417631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study.
    Amir O; Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman L; Ash N; Alroy-Preis S; Huppert A; Milo R
    Lancet Infect Dis; 2023 Jan; 23(1):67-73. PubMed ID: 36096146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
    Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
    JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
    Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
    JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine.
    Patalon T; Gazit S; Pitzer VE; Prunas O; Warren JL; Weinberger DM
    JAMA Intern Med; 2022 Feb; 182(2):179-184. PubMed ID: 34846533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
    Barda N; Dagan N; Cohen C; Hernán MA; Lipsitch M; Kohane IS; Reis BY; Balicer RD
    Lancet; 2021 Dec; 398(10316):2093-2100. PubMed ID: 34756184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
    Moreira ED; Kitchin N; Xu X; Dychter SS; Lockhart S; Gurtman A; Perez JL; Zerbini C; Dever ME; Jennings TW; Brandon DM; Cannon KD; Koren MJ; Denham DS; Berhe M; Fitz-Patrick D; Hammitt LL; Klein NP; Nell H; Keep G; Wang X; Koury K; Swanson KA; Cooper D; Lu C; Türeci Ö; Lagkadinou E; Tresnan DB; Dormitzer PR; Şahin U; Gruber WC; Jansen KU;
    N Engl J Med; 2022 May; 386(20):1910-1921. PubMed ID: 35320659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study.
    Gazit S; Saciuk Y; Perez G; Peretz A; Pitzer VE; Patalon T
    BMJ; 2022 May; 377():e071113. PubMed ID: 35609888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
    Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
    Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 87.